---
document_datetime: 2025-12-21 08:02:24
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/pregabalin-viatris.html
document_name: pregabalin-viatris.html
version: success
processing_time: 0.1364055
conversion_datetime: 2025-12-24 04:39:23.515252
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Pregabalin Viatris (previously Pregabalin Mylan)

[RSS](/en/individual-human-medicine.xml/66361)

##### Authorised

This medicine is authorised for use in the European Union

pregabalin Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Pregabalin Viatris (previously Pregabalin Mylan)](#news-on)
- [More information on Pregabalin Mylan](#more-information-on-pregabalin-mylan-1287)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Pregabalin Viatris is a medicine used to treat adults with the following conditions:

• neuropathic pain (pain due to nerve damage), including peripheral neuropathic pain, such as the pain experienced by patients with diabetes or herpes zoster (shingles), and central neuropathic pain, such as the pain experienced by patients who have had a spinal cord injury;

• epilepsy, where it is used as an 'add-on' to other epilepsy treatment in patients who have partial seizures (epileptic fits starting in one specific part of the brain);

• generalised anxiety disorder (long-term anxiety or nervousness about everyday matters).

Pregabalin Viatris contains the active substance pregabalin and is a 'generic medicine'. This means that Pregabalin Viatris contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU. The reference medicine for Pregabalin Viatris is Lyrica. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/other/questions-and-answers-generic-medicines_en.pdf) .

Expand section

Collapse section

## How is Pregabalin Viatris used?

Pregabalin Viatris is available as capsules to be taken by mouth and can only be obtained with a prescription.

For more information about using Pregabalin Viatris, see the package leaflet or contact your doctor or pharmacist.

## How does Pregabalin Viatris work?

The active substance in Pregabalin Viatris, pregabalin, is similar in structure to the body's own 'neurotransmitter' gamma-amino butyric acid (GABA), but has very different biological effects. Neurotransmitters are chemicals that allow nerve cells to communicate with each other. The exact way that pregabalin works is not fully understood, but it is thought to affect the way that calcium enters nerve cells. This reduces the activity of some of the nerve cells in the brain and spinal cord, reducing the release of other neurotransmitters that are involved in epilepsy and anxiety.

## How has Pregabalin Viatris been studied?

Studies on the benefits and risks of the active substance in the approved uses have already been carried out with the reference medicine, Lyrica, and do not need to be repeated for Pregabalin Viatris.

As for every medicine, the company provided studies on the quality of Pregabalin Viatris. The company also carried out studies that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Pregabalin Viatris?

Because Pregabalin Viatris is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Pregabalin Viatris authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Pregabalin Viatris has been shown to have comparable quality and to be bioequivalent to Lyrica. Therefore, the Agency's view was that, as for Lyrica, the benefits of Pregabalin Viatris outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Pregabalin Viatris?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pregabalin Viatris have been included in the summary of product characteristics and the package leaflet. Any additional measures in place for Lyrica also apply to Pregabalin Viatris where appropriate.

As for all medicines, data on the use of Pregabalin Viatris are continuously monitored. Suspected side effects reported with Pregabalin Viatris are carefully evaluated and any necessary action taken to protect patients.

## Other information about Pregabalin Viatris

Pregabalin Mylan received a marketing authorisation valid throughout the EU on 25 June 2015.

The name of the medicine was changed to Pregabalin Viatris on 24 July 2024.

Pregabalin Viatris : EPAR - Medicine overview

Reference Number: EMA/284779/2024

English (EN) (176.53 KB - PDF)

**First published:** 31/07/2015

**Last updated:** 08/01/2025

[View](/en/documents/overview/pregabalin-viatris-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-23)

български (BG) (178.14 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

08/01/2025

[View](/bg/documents/overview/pregabalin-mylan-epar-medicine-overview_bg.pdf)

español (ES) (154.44 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

08/01/2025

[View](/es/documents/overview/pregabalin-mylan-epar-medicine-overview_es.pdf)

čeština (CS) (175.07 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

08/01/2025

[View](/cs/documents/overview/pregabalin-mylan-epar-medicine-overview_cs.pdf)

dansk (DA) (152.4 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

08/01/2025

[View](/da/documents/overview/pregabalin-mylan-epar-medicine-overview_da.pdf)

Deutsch (DE) (156.93 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

08/01/2025

[View](/de/documents/overview/pregabalin-mylan-epar-medicine-overview_de.pdf)

eesti keel (ET) (152.13 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

08/01/2025

[View](/et/documents/overview/pregabalin-mylan-epar-medicine-overview_et.pdf)

ελληνικά (EL) (177.88 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

08/01/2025

[View](/el/documents/overview/pregabalin-mylan-epar-medicine-overview_el.pdf)

français (FR) (155.52 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

08/01/2025

[View](/fr/documents/overview/pregabalin-mylan-epar-medicine-overview_fr.pdf)

hrvatski (HR) (172.58 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

08/01/2025

[View](/hr/documents/overview/pregabalin-mylan-epar-medicine-overview_hr.pdf)

italiano (IT) (152.21 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

08/01/2025

[View](/it/documents/overview/pregabalin-mylan-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (191.38 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

08/01/2025

[View](/lv/documents/overview/pregabalin-mylan-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (175.19 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

08/01/2025

[View](/lt/documents/overview/pregabalin-mylan-epar-medicine-overview_lt.pdf)

magyar (HU) (175.45 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

08/01/2025

[View](/hu/documents/overview/pregabalin-mylan-epar-medicine-overview_hu.pdf)

Malti (MT) (177.12 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

08/01/2025

[View](/mt/documents/overview/pregabalin-mylan-epar-medicine-overview_mt.pdf)

Nederlands (NL) (153.69 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

08/01/2025

[View](/nl/documents/overview/pregabalin-mylan-epar-medicine-overview_nl.pdf)

polski (PL) (178.26 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

08/01/2025

[View](/pl/documents/overview/pregabalin-mylan-epar-medicine-overview_pl.pdf)

português (PT) (154.98 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

08/01/2025

[View](/pt/documents/overview/pregabalin-mylan-epar-medicine-overview_pt.pdf)

română (RO) (172.64 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

08/01/2025

[View](/ro/documents/overview/pregabalin-mylan-epar-medicine-overview_ro.pdf)

slovenčina (SK) (175.51 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

08/01/2025

[View](/sk/documents/overview/pregabalin-mylan-epar-medicine-overview_sk.pdf)

slovenščina (SL) (172.3 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

08/01/2025

[View](/sl/documents/overview/pregabalin-mylan-epar-medicine-overview_sl.pdf)

Suomi (FI) (151.52 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

08/01/2025

[View](/fi/documents/overview/pregabalin-mylan-epar-medicine-overview_fi.pdf)

svenska (SV) (151.82 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

08/01/2025

[View](/sv/documents/overview/pregabalin-mylan-epar-medicine-overview_sv.pdf)

Pregabalin Mylan : EPAR - Risk-management-plan summary

Reference Number: EMA/285072/2015

English (EN) (103.79 KB - PDF)

**First published:** 31/07/2015

**Last updated:** 03/09/2015

[View](/en/documents/rmp-summary/pregabalin-mylan-epar-risk-management-plan-summary_en.pdf)

## Product information

Pregabalin Viatris : EPAR - Product Information

English (EN) (324.77 KB - PDF)

**First published:** 31/07/2015

**Last updated:** 19/12/2025

[View](/en/documents/product-information/pregabalin-viatris-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-748)

български (BG) (683.9 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

19/12/2025

[View](/bg/documents/product-information/pregabalin-viatris-epar-product-information_bg.pdf)

español (ES) (467.2 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

19/12/2025

[View](/es/documents/product-information/pregabalin-viatris-epar-product-information_es.pdf)

čeština (CS) (514.71 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

19/12/2025

[View](/cs/documents/product-information/pregabalin-viatris-epar-product-information_cs.pdf)

dansk (DA) (538.52 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

19/12/2025

[View](/da/documents/product-information/pregabalin-viatris-epar-product-information_da.pdf)

Deutsch (DE) (457.73 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

19/12/2025

[View](/de/documents/product-information/pregabalin-viatris-epar-product-information_de.pdf)

eesti keel (ET) (534.48 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

19/12/2025

[View](/et/documents/product-information/pregabalin-viatris-epar-product-information_et.pdf)

ελληνικά (EL) (480.74 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

19/12/2025

[View](/el/documents/product-information/pregabalin-viatris-epar-product-information_el.pdf)

français (FR) (535.93 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

19/12/2025

[View](/fr/documents/product-information/pregabalin-viatris-epar-product-information_fr.pdf)

hrvatski (HR) (618.73 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

19/12/2025

[View](/hr/documents/product-information/pregabalin-viatris-epar-product-information_hr.pdf)

íslenska (IS) (572.16 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

19/12/2025

[View](/is/documents/product-information/pregabalin-viatris-epar-product-information_is.pdf)

italiano (IT) (292.51 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

19/12/2025

[View](/it/documents/product-information/pregabalin-viatris-epar-product-information_it.pdf)

latviešu valoda (LV) (467.3 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

19/12/2025

[View](/lv/documents/product-information/pregabalin-viatris-epar-product-information_lv.pdf)

lietuvių kalba (LT) (517.45 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

19/12/2025

[View](/lt/documents/product-information/pregabalin-viatris-epar-product-information_lt.pdf)

magyar (HU) (452.1 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

19/12/2025

[View](/hu/documents/product-information/pregabalin-viatris-epar-product-information_hu.pdf)

Malti (MT) (673.54 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

19/12/2025

[View](/mt/documents/product-information/pregabalin-viatris-epar-product-information_mt.pdf)

Nederlands (NL) (599.49 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

19/12/2025

[View](/nl/documents/product-information/pregabalin-viatris-epar-product-information_nl.pdf)

norsk (NO) (382.04 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

19/12/2025

[View](/no/documents/product-information/pregabalin-viatris-epar-product-information_no.pdf)

polski (PL) (566.63 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

19/12/2025

[View](/pl/documents/product-information/pregabalin-viatris-epar-product-information_pl.pdf)

português (PT) (514.71 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

19/12/2025

[View](/pt/documents/product-information/pregabalin-viatris-epar-product-information_pt.pdf)

română (RO) (638.08 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

19/12/2025

[View](/ro/documents/product-information/pregabalin-viatris-epar-product-information_ro.pdf)

slovenčina (SK) (632.47 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

19/12/2025

[View](/sk/documents/product-information/pregabalin-viatris-epar-product-information_sk.pdf)

slovenščina (SL) (403.45 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

19/12/2025

[View](/sl/documents/product-information/pregabalin-viatris-epar-product-information_sl.pdf)

Suomi (FI) (553.04 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

19/12/2025

[View](/fi/documents/product-information/pregabalin-viatris-epar-product-information_fi.pdf)

svenska (SV) (547.73 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

19/12/2025

[View](/sv/documents/product-information/pregabalin-viatris-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000319152 19/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Pregabalin Viatris : EPAR - All authorised presentations

English (EN) (41.33 KB - PDF)

**First published:** 31/07/2015

**Last updated:** 11/09/2024

[View](/en/documents/all-authorised-presentations/pregabalin-viatris-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-634)

български (BG) (103.35 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

11/09/2024

[View](/bg/documents/all-authorised-presentations/pregabalin-mylan-epar-all-authorised-presentations_bg.pdf)

español (ES) (98.68 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

11/09/2024

[View](/es/documents/all-authorised-presentations/pregabalin-mylan-epar-all-authorised-presentations_es.pdf)

čeština (CS) (62.26 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

11/09/2024

[View](/cs/documents/all-authorised-presentations/pregabalin-mylan-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (58.22 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

11/09/2024

[View](/da/documents/all-authorised-presentations/pregabalin-mylan-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (62.16 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

11/09/2024

[View](/de/documents/all-authorised-presentations/pregabalin-mylan-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (104.48 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

11/09/2024

[View](/et/documents/all-authorised-presentations/pregabalin-mylan-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (59.45 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

11/09/2024

[View](/el/documents/all-authorised-presentations/pregabalin-mylan-epar-all-authorised-presentations_el.pdf)

français (FR) (39.31 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

11/09/2024

[View](/fr/documents/all-authorised-presentations/pregabalin-mylan-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (80.23 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

11/09/2024

[View](/hr/documents/all-authorised-presentations/pregabalin-mylan-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (57.2 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

11/09/2024

[View](/is/documents/all-authorised-presentations/pregabalin-mylan-epar-all-authorised-presentations_is.pdf)

italiano (IT) (60.16 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

11/09/2024

[View](/it/documents/all-authorised-presentations/pregabalin-mylan-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (104.78 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

11/09/2024

[View](/lv/documents/all-authorised-presentations/pregabalin-mylan-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (107.29 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

11/09/2024

[View](/lt/documents/all-authorised-presentations/pregabalin-mylan-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (57.61 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

11/09/2024

[View](/hu/documents/all-authorised-presentations/pregabalin-mylan-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (63.04 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

11/09/2024

[View](/mt/documents/all-authorised-presentations/pregabalin-mylan-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (59.58 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

11/09/2024

[View](/nl/documents/all-authorised-presentations/pregabalin-mylan-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (42.13 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

11/09/2024

[View](/no/documents/all-authorised-presentations/pregabalin-mylan-epar-all-authorised-presentations_no.pdf)

polski (PL) (38.15 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

11/09/2024

[View](/pl/documents/all-authorised-presentations/pregabalin-mylan-epar-all-authorised-presentations_pl.pdf)

português (PT) (23.73 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

11/09/2024

[View](/pt/documents/all-authorised-presentations/pregabalin-mylan-epar-all-authorised-presentations_pt.pdf)

română (RO) (60.79 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

11/09/2024

[View](/ro/documents/all-authorised-presentations/pregabalin-mylan-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (70.61 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

11/09/2024

[View](/sk/documents/all-authorised-presentations/pregabalin-mylan-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (50.93 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

11/09/2024

[View](/sl/documents/all-authorised-presentations/pregabalin-mylan-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (56.78 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

11/09/2024

[View](/fi/documents/all-authorised-presentations/pregabalin-mylan-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (41.65 KB - PDF)

**First published:**

31/07/2015

**Last updated:**

11/09/2024

[View](/sv/documents/all-authorised-presentations/pregabalin-mylan-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Pregabalin Viatris (previously Pregabalin Mylan) Active substance pregabalin International non-proprietary name (INN) or common name pregabalin Therapeutic area (MeSH)

- Anxiety Disorders
- Epilepsy

Anatomical therapeutic chemical (ATC) code N02BF02

### Pharmacotherapeutic group

Antiepileptics

### Therapeutic indication

**Neuropathic pain**

Pregabalin Viatris is indicated for the treatment of peripheral and central neuropathic pain in adults.

**Epilepsy** Pregabalin Viatris is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

**Generalised Anxiety Disorder** Pregabalin Viatris is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.

## Authorisation details

EMA product number EMEA/H/C/004078

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Viatris Limited

Damastown Industrial Park Mulhuddart Dublin 15 Ireland

Opinion adopted 22/04/2015 Marketing authorisation issued 24/06/2015 Revision 23

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Pregabalin Viatris : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (171.61 KB - PDF)

**First published:** 16/05/2024

**Last updated:** 19/12/2025

[View](/en/documents/procedural-steps-after/pregabalin-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Pregabalin Mylan : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (205.34 KB - PDF)

**First published:** 04/02/2016

**Last updated:** 16/05/2024

[View](/en/documents/procedural-steps-after/pregabalin-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Pregabalin Mylan : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/90129/2015

English (EN) (599.59 KB - PDF)

**First published:** 31/07/2015

**Last updated:** 31/07/2015

[View](/en/documents/assessment-report/pregabalin-mylan-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Pregabalin Mylan

Adopted

Reference Number: EMA/CHMP/238445/2015 Rev. 1

English (EN) (66.82 KB - PDF)

**First published:** 24/04/2015

**Last updated:** 29/05/2015

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-pregabalin-mylan_en.pdf)

#### News on Pregabalin Viatris (previously Pregabalin Mylan)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 April 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-april-2015) 24/04/2015

#### More information on Pregabalin Mylan

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-885)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 19/12/2025

## Share this page

[Back to top](#main-content)